Berend Olivier
Berend Olivier obtained a Ph.D. in Neurobiology from Groningen University, the Netherlands. He worked at Solvay Pharmaceuticals for 22 years leading the research and development of new antidepressants, antipsychotics, anxiolytics, and serenics. He was heavily involved in the research and development of fluvoxamine, a marketed antidepressant, anxiolytic, and anti-OCD medication. From 1999 to 2001, he worked in New York to start a biotech company called PsychoGenics Inc., which develops psychiatric and neurological (genetic) models to screen, find, and develop new central nervous system drugs. From 1992 to 2014, he was a Professor of CNS Pharmacology at Utrecht University, the Netherlands, performing research on animal models, brain mechanisms, and pharmacology of psychiatric disorders. Since 2014, he has been developing animal models of male sexual disorders in the hope of finding new medicines for premature and delayed ejaculation.